Aktuellt
SENASTE
OssDsign reported its first post-market safety data, with no device-related complaints nor device-related adverse events. The report revealed valuable information in regard to sales quantities and number of clinics using the product; both numbers were higher than expected. With the Q3 report due next week, we will not be doing any estimate revision for now but note that the risks to our estimates are likely on the upside. Reiterate mid-point of SEK 10 per share.
LÄS MER
